US STOCK
TGTX Stock Analysis
US stocks · market data · technical indicators
TG Therapeutics, Inc.
TGTXUS stocksQuote delayed 15 min
10/27 上午11:47 updated
$54.79
+0.62+1.14%
Open
$54.81
High
$55.49
Low
$53.71
Volume
118.75萬
TGTX price history
-2.49%Open
56.19
Latest
54.79
High
56.19
Low
52.19
Average
54.33
Advertisement
Financial snapshot
TGTX - TG Therapeutics, Inc.
EPS
2.78USD
Forward EPS
2.71USD
P/E
19.71x
Forward P/E
20.23x
P/B
12.87x
ROE
100.28%
ROA
7.28%
Operating margin
9.02%
Profit margin
55.22%
Revenue growth
70.30%
Earnings growth
-70.60%
Dividend yield
0.00%
Financial statements
| 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|---|
| Revenue | $240.34M | $204.92M | $192.57M | $161.71M | $141.15M |
| Gross profit | $199.14M | $171.41M | $154.43M | $133.62M | $122.21M |
| Operating income | $21.67M | $34.80M | $50.49M | $29.36M | $34.84M |
| Net income | $7.78M | $19.78M | $23.04M | $390.89M | $28.19M |
| Basic EPS | 0.05 | 0.14 | 0.16 | 2.69 | 0.19 |
| Diluted EPS | 0.05 | 0.12 | 0.14 | 2.43 | 0.17 |
Estimates vs actuals
Next earnings
2026-11-02
EPS estimate
0.26
Revenue estimate
$245.45M
Last surprise
-88.60%
| Date | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-11-02 | 0.26 | Not reported | — |
| 2026-08-03 | 0.44 | 0.05 | -88.60% |
| 2026-05-06 | 0.28 | 0.18 | -35.09% |
| 2026-02-26 | 0.33 | 0.14 | -57.48% |
| 2025-11-03 | 0.22 | 0.16 | -26.30% |
| 2025-08-04 | 0.29 | 0.17 | -40.85% |
| 2025-05-05 | 0.17 | 0.03 | -82.76% |
| 2025-03-03 | 0.17 | 0.15 | -12.33% |
| 2024-11-04 | 0.03 | 0.02 | -40.92% |
| 2024-08-06 | -0.04 | 0.04 | +209.44% |
| 2024-05-01 | -0.04 | -0.07 | -55.56% |
| 2024-02-28 | -0.11 | -0.10 | +11.92% |
Institutional holders
| Institution | Quarter | Value held | Portfolio weight |
|---|---|---|---|
| VANGUARD GROUP INC | 2025-12-31 | $472.2M | 0.01% |
| STATE STREET CORP | 2026-06-30 | $427.8M | 0.01% |
| BlackRock Inc. | 2024-06-30 | $202.6M | 0.00% |
| TWO SIGMA INVESTMENTS, LP | 2026-06-30 | $135.6M | 0.10% |
| RENAISSANCE TECHNOLOGIES LLC | 2026-06-30 | $37.3M | 0.05% |
| CITADEL ADVISORS LLC | 2026-06-30 | $29.5M | 0.00% |
| Bridgewater Associates, LP | 2026-06-30 | $23.6M | 0.10% |
13F quarterly filings. Reporting periods differ by institution; value and weight reflect each institution's own latest quarter.
Analyst ratings
Mean target
$69.71
Target range
$21.00 – $86.00
Implied upside
27.24%
Strong buy
1
Buy
6
Hold
0
Sell
0
Strong sell
1
Advertisement